Personalis Inc.: Precision Medicine at the Commercial Turning Point: Can This Biotech Bet Pay Off?

The business model is rapidly transforming from a pure research service provider to a clinical diagnostics specialist, whose ultra-sensitive liquid biopsies (NeXT Personal ) can detect cancer relapses months before conventional methods. The recent groundbreaking reimbursement commitments from the US health insurance Medicare for breast and lung cancer act as a massive lever to multiply clinical test volumes to projected 43,000 to 45,000 units. Although the company is still operating at a loss due to high investments in sales development and...